Skip to main navigation

Sagimet Biosciences

Main navigation

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact

News Releases

Year

11/26/2024

Sagimet Biosciences to Participate in the Piper Sandler 36th Annual Healthcare Conference

11/18/2024

Sagimet Biosciences Presents Clinical Denifanstat and Preclinical FASN Inhibitor Data at AASLD - The Liver Meeting® 2024

11/14/2024

Sagimet Biosciences Reports Third Quarter 2024 Financial Results and Provides Corporate Updates

11/7/2024

Sagimet Biosciences to Participate in the UBS Global Healthcare Conference

10/29/2024

Sagimet Biosciences Announces Successful Completion of End-of-Phase 2 Interactions with FDA on the Development of Denifanstat for MASH; Phase 3 Program Initiation Expected by End of 2024

10/16/2024

Sagimet Biosciences Announces Upcoming Presentations at AASLD - The Liver Meeting® 2024

10/11/2024

Sagimet Biosciences Announces Publication of Results from Phase 2b FASCINATE-2 Clinical Trial of Denifanstat in Biopsy-Confirmed F2/F3 MASH in The Lancet Gastroenterology & Hepatology

10/1/2024

Sagimet Receives FDA Breakthrough Therapy Designation for Denifanstat in MASH

10/1/2024

Sagimet Biosciences to Present at the H.C. Wainwright 8th Annual MASH Virtual Conference and Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

9/12/2024

Sagimet Announces Oral Presentation at the 8th Annual MASH Drug Development Summit

Pagination

Current page 1
Page 2
Page 3
Next page
Last page

Site Map

About
Science
Investors
Programs
Contact

Contact Us

Business Development:
bd@sagimet.com

Investors:
ir@sagimet.com

Media:
media@sagimet.com

© 2024 Sagimet Biosciences Inc. All Rights Reserved.

Close line1 Close line2

Main navigation

About
Science
- FASN
- Posters/Publications
Investors & Media
Programs
Contact